Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

Fig. 1

The impact of genetic variants on progression-free survival (PFS) of lung carcinoma patients with EGFR-mutant (M +) or EGFR-wildtype (WT) tumors. A Forest plot showing the effects of variants with a significant impact on PFS of patients with EGFR M + patients treated with EGFR tyrosine kinase inhibitors (TKIs) compared to PFS of patients with EGFR-WT tumors receiving another firstline treatment. B-E Kaplan–Meier curves for PFS. Patients with EGFR-mutant tumors were stratified according to the number of variants in the CTBP2 gene (B), the absence or presence of at least one variant in the HLA-DRB5 (C), in KIR3DL1 (D), or in the KIR3DL2 gene (E). F Heatmap summarizing the effects of all these variants on PFS of patients with EGFR M + tumors

Back to article page

Molecular Cancer

ISSN: 1476-4598